Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

J&J spinout readying first two Centyrin-oligo conjugates for the clinic

By  KAren Tkach Tuzman, SEnior Editor
January 6, 2021 1:30 AM UTC

A deal with antisense heavyweight Ionis attracted the investor firepower fueling Aro’s transition from platform development to product advancement.

Aro Biotherapeutics Co. raised an $88 million series A round Tuesday led by Northpond Ventures and Cowen Healthcare Investments. HealthCap, BVF Partners L.P. and Ridgeback Capital also participated, along with existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv and Ionis Pharmaceuticals Inc. (NASDAQ:IONS). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Aro Biotherapeutics Co.

Avidity Biosciences Inc.

Dyne Therapeutics Inc.

Ionis Pharmaceuticals Inc.